Marketing Research and Analysis

Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers. While the number of biosimilar approvals in the US still lags behind Europe, a solid foundation continues to be laid by multiple key stakeholder groups. Successes have been seen in key areas, including the approval of the first monoclonal antibody (mAb) biosimilar, Inflectra, and regulatory refinement. But what of the critical opportunities and challenges in the US? How do payers perceive what’s important, and what can companies do to ensure commercial success? WHAT FEATURES DOES THE REPORT PROVIDES? In-depth interviews reveal over 200 unique and candid insights from ten 10 expert US payers from government and commercial backgrounds Overview of the key areas of progress in the US biosimilars market during the last year, including an analysis of critical market shaping issues such as clinical data, regulatory progress, commercialisation, legal and policy. The ...